biomarkers for glp-1 agonists Repurposing glucagon-like peptide-1 receptor the treatment of neurodegenerative disorders GLP1 agonists: current and future

The authors hypothesized that an increasing GSH concentration represents an adaptive mechanism to increase antioxidant defenses, which results in fewer symptoms, reduced airway reactivity, and milder disease in patients with asthma

Humanized gnotobiotic mouse experiments C57BL/6JNarl male germ-free mice (812 weeks of age) were used to establish four study groups of hGM model through fecal microbiota transplantation (FMT) from donors of two OCCT-defined high-TMAO producers (O15 and O32) and two OCCT-defined low-TMAO producers (V12 and V25)

However, TMAO improved risk stratification for death/MI at 6 months by down-classifying the risk of some patients (Suzuki et al., 2017)

Allow 2-4 weeks to assess tolerance before increasing